A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip

NCT01618708 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

357

Enrollment

INDUSTRY

Sponsor class

Conditions

Osteoarthritis, Hip

Interventions

DEVICE: Synvisc-One (hylan G-F 20)
DEVICE: Placebo

Sponsor

Genzyme, a Sanofi Company